The measure of progress will be how effectively increased filings translate into productive technologies and economic value.

India Inc. witnessed a significant turnaround in the December quarter, with approximately 50 listed companies swinging from losses to profits. This broad-based recovery spans sectors like aviation, ...

DengiAll, which is Panacea Biotec's tetravalent live-attenuated vaccine, uses weakened strains of all four DENV serotypes. As ...

As dengue surges globally, an Indian vaccine candidate has entered the final stage of testing, raising hopes for one of the ...

Dengue infects up to 400 million people and kills thousands every year but an Indian company is now inching closer to a ...

Hoping to stem the global epidemic of Dengue, Panacea Biotec has begun final Phase III trials of its vaccine ...

An Indian company, Panacea Biotec, is nearing a breakthrough with what could be the country's first indigenous, single-shot dengue vaccine, DengiAll, after two decades of development.

India’s Panacea Biotec begins Phase III trials of its single-dose dengue vaccine candidate DengiAll, offering hope amid ...

As dengue surges globally, an Indian vaccine candidate has entered the final stage of testing, raising hopes for one of the world's first single-dose shots.

As dengue surges globally, an Indian vaccine candidate has entered the final stage of testing, raising hopes for one of the ...

Net profit of Panacea Biotec declined 11.95% to Rs 3.98 crore in the quarter ended December 2025 as against Rs 4.52 crore during the previous quarter ended December 2024. Sales rose 1.04% to Rs 165.19 ...

Doctor-focused fintech adds senior leaders in marketing, compliance, and medical education finance as it advances its vision to become the financial operating system for doctors Panacea Financial, the ...